Industry: Pharmaceuticals, Biotechnology
BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co, Ltd, Japan’s leading pharmaceutical and largest biotech company. BioWa is the exclusive worldwide licensor of PotelligentÔ Technology. PotelligentÔ Technology creates high antibody -dependent cellular cytotoxicity (ADCC) monoclonal antibodies. ADCC is a critical function of the immune system that enhances the ability of antibodies to kill tumor cells. The enhancement of ADCC is seen up to 100 fold in vitro. BioWa is currently developing ADCC enhanced monoclonal antibody-based therapeutics to fight cancer, asthma and other life-threatening and debilitating diseases and both BioWa and Kyowa have PotelligentÔ antibody products in various clinical ( www.biowa.com )
BioWa , Inc.
202 Carnegie Center Suite 101
Princeton, New Jersey 08540
USA
Tel: (609) 580-7500
Fax: (609) 919-1108